Treatment options for advanced urothelial cancer after …
To describe the current treatment landscape in advanced urothelial cancer (aUC)/metastatic urothelial cancer and in particular to review the relevant literature highlighting recent advances …
Receiver operating characteristic - Wikipedia
The ROC curve was first developed by electrical engineers and radar engineers during World War II for detecting enemy objects in battlefields, starting in 1941, which led to its name ("receiver …
The New 2017 Appropriate Use Criteria for Coronary ... - SCAI
Jul 5, 2017 · SCAI has again collaborated with the American College of Cardiology, the American Heart Association, the Society of Thoracic Surgery and other organizations to develop …
2023 Multimodality Appropriate Use Criteria for Chronic Coronary ...
May 25, 2023 · An upcoming AUC document will provide guidance on multimodality imaging in cardiovascular evaluation of patients undergoing nonurgent, noncardiac surgery. Clinical …
Newest AUC Provide Clinical Guidance on Cardiac Implantable …
Jan 13, 2025 · New multisociety Appropriate Use Criteria (AUC) published in JACC focus on cardiac implantable electronic devices (CIEDs), specifically ICDs, CRT and pacing. The …
AUC are developed by the American College of Cardiology (ACC), in partnership with cardiology subspecialty societies, to help guide the appropriate use of cardiovascular tests and procedures.
A phase II trial of regorafenib for advanced urothelial cancer (aUC ...
Feb 19, 2020 · Methods: We conducted a single arm, non-randomized Phase II study (NCT02459119) of regorafenib for aUC following chemotherapy. All patients (pts) started at …
Phase II California Cancer Consortium Trial of Gemcitabine …
Aug 7, 2019 · The results of this small phase II clinical trial show that the gemcitabine-eribulin combination has activity in metastatic urothelial carcinoma and is well tolerated in the cisplatin …
Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in …
Jan 22, 2013 · Although gemcitabine and carboplatin (GCa) is a standard option for patients with advanced urothelial cancer (UC) who are ineligible for cisplatin, outcomes remain poor. This …
Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin …
Chemonaive patients with IIIB/IV NSCLC and a performance status of 0–1 were randomly assigned to a biweekly regimen (paclitaxel 135 mg/m 2 with carboplatin area under the curve …